Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NBRV
CUSIPN/A
Phone610-816-6640
Debt
Debt-to-Equity Ratio0.01
Current Ratio7.52
Quick Ratio7.52
Price-To-Earnings
Trailing P/E Ratio-1.04
Forward P/E Ratio-1.65
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.32 million
Price / Sales317.42
Cash FlowN/A
Price / CashN/A
Book Value$2.24 per share
Price / Book1.13
Profitability
EPS (Most Recent Fiscal Year)($2.49)
Net Income$-74,350,000.00
Net Margins-642.38%
Return on Equity-77.40%
Return on Assets-66.91%
Miscellaneous
Employees88
Outstanding Shares664,840,000
Market Cap$1.70 billion
Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions
What is Nabriva Therapeutics' stock symbol?
Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."
How were Nabriva Therapeutics' earnings last quarter?
Nabriva Therapeutics PLC - (NASDAQ:NBRV) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.04. The biotechnology company had revenue of $0.85 million for the quarter, compared to analysts' expectations of $1.16 million. Nabriva Therapeutics had a negative return on equity of 77.40% and a negative net margin of 642.38%. View Nabriva Therapeutics' Earnings History.
When is Nabriva Therapeutics' next earnings date?
What price target have analysts set for NBRV?
7 equities research analysts have issued 1-year target prices for Nabriva Therapeutics' stock. Their forecasts range from $5.00 to $20.00. On average, they expect Nabriva Therapeutics' share price to reach $13.40 in the next year. This suggests a possible upside of 427.6% from the stock's current price. View Analyst Price Targets for Nabriva Therapeutics.
What is the consensus analysts' recommendation for Nabriva Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nabriva Therapeutics.
What are Wall Street analysts saying about Nabriva Therapeutics stock?
Here are some recent quotes from research analysts about Nabriva Therapeutics stock:
- 1. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (8/1/2018)
- 2. Needham & Company LLC analysts commented, "Nabriva announced plans to acquire Zavante, a private company developing IV fosfomycin (Contepo) for the U.S. market. Zavante shareholders will receive 8.2M shares of NBRV stock and up to $97.5M in milestone payments (cash or shares) if certain regulatory/ commercial milestones are met. Although we have modest expectations for new IV antibiotics like Contepo in the hospital Gram- negative space, we believe the transaction is a net positive for Nabriva. No additional commercial infrastructure is needed beyond what is already planned for lefamulin. Zavante announced Phase 3 results 505(b)(2) submission is expected 4Q18. BUY. We recognize Nabriva needs cash, but believe lefamulin is a substantially underappreciated asset that will be relevant outside the challenging hospital setting." (7/25/2018)
- 3. HC Wainwright analysts commented, "Updated Results from SITC Confirm IMO-2125 Clinical Benefit; Reiterate Buy IMO-2125 activates innate immune response against tumor. Last week we attended the annual meeting for Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. At the conference, Dr. Haymaker from MD Anderson Cancer Center presented additional results from the ongoing Phase 1/2 clinical study of IMO-2125, a TLR9 agonist from Idera. Recall, IMO-2125 is being investigated as a combinational therapy together with Bristol-Myers Squibb’s (BMY; not rated) Yervoy (ipilimumab) for the treatment of PD-1 refractory melanoma. Previously, it was reported that the combination of IMO-2125 and ipilimumab achieved an overall response rate (ORR) of 44%. The updated results presented at the SITC conference included an additional patient with confirmed response, which improved the ORR from the study to 50% (5 out of 10 patients). Importantly, gene expression analysis in patients’ tumor biopsies, taken 24 hours after IMO-2125 injections, suggests that IMO-2125 upregulates interferon-alpha production, promotes dendritic cells maturation and the inflow of macrophages at the tumor site. Moreover, considering that ipilimumab has not yet been administered at the time of the biopsy, the observed activation of immune system can be fully attributed to IMO-2125, rather than the drug combination. In our view, these results provide additional confidence in the clinical activity of IMO-2125 and potential success of the planned Phase 3 study, which is expected to start in 1Q18." (11/16/2017)
Are investors shorting Nabriva Therapeutics?
Nabriva Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,574,112 shares, an increase of 28.5% from the August 15th total of 1,224,631 shares. Based on an average daily trading volume, of 315,802 shares, the days-to-cover ratio is currently 5.0 days. Currently, 3.4% of the shares of the company are sold short. View Nabriva Therapeutics' Current Options Chain.
Who are some of Nabriva Therapeutics' key competitors?
Some companies that are related to Nabriva Therapeutics include Ionis Pharmaceuticals (IONS), Catalent (CTLT), Alkermes (ALKS), GALAPAGOS NV/S (GLPG), Dr.Reddy's Laboratories (RDY), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM) and Endo International (ENDP).
Who are Nabriva Therapeutics' key executives?
Nabriva Therapeutics' management team includes the folowing people:
- Mr. Steven P. Gelone, Pres & COO (Age 50)
- Dr. Colin Broom, Consultant & Director (Age 62)
- Mr. Gary L. Sender, Chief Financial Officer (Age 56)
- Mr. Theodore R. Schroeder, Chief Exec. Officer (Age 63)
- Mr. Thomas Lembck, Chief Information Officer
Has Nabriva Therapeutics been receiving favorable news coverage?
News coverage about NBRV stock has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nabriva Therapeutics earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Nabriva Therapeutics.
Who are Nabriva Therapeutics' major shareholders?
Nabriva Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Novo Holdings A S (0.43%), Hillhouse Capital Management Ltd. (0.11%), Prosight Management LP (0.06%), Dimensional Fund Advisors LP (0.71%), venBio Partners L.P. (0.03%) and Wedbush Securities Inc. (0.22%). Company insiders that own Nabriva Therapeutics stock include Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, George Harrison Talbot, Hbm Healthcare Investments (Ca, Jennifer Schranz, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Nabriva Therapeutics.
Which institutional investors are selling Nabriva Therapeutics stock?
Which institutional investors are buying Nabriva Therapeutics stock?
NBRV stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Prosight Management LP, Wedbush Securities Inc. and Bank of America Corp DE. Company insiders that have bought Nabriva Therapeutics stock in the last two years include Colin Md Broom, Daniel D Burgess, Francesco Maria Lavino, Gary Sender, Jennifer Schranz, Robert Crotty, Stephen W Webster and Vivo Capital Viii, Llc. View Insider Buying and Selling for Nabriva Therapeutics.
How do I buy shares of Nabriva Therapeutics?
Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nabriva Therapeutics' stock price today?
One share of NBRV stock can currently be purchased for approximately $2.54.
How big of a company is Nabriva Therapeutics?
Nabriva Therapeutics has a market capitalization of $1.70 billion and generates $5.32 million in revenue each year. The biotechnology company earns $-74,350,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Nabriva Therapeutics employs 88 workers across the globe.
How can I contact Nabriva Therapeutics?
Nabriva Therapeutics' mailing address is 56 FITZWILLIAM SQUARE, DUBLIN L2, 19406. The biotechnology company can be reached via phone at 610-816-6640 or via email at [email protected]
MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
